{
  "docId": "019de070-d3cd-70da-8da9-11fac56c0e6a",
  "docSlug": "a10c554cbe4a4cf1ea91fc4610f64010",
  "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 27 slides",
  "authorId": "neurobo-pharmaceuticals",
  "authorName": "NeuroBo Pharmaceuticals",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 21,
  "pageCount": 27,
  "prevPage": 20,
  "nextPage": 22,
  "slideType": "context",
  "function": "establish_context",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-d3cd-70da-8da9-11fac56c0e6a/21",
  "deckHref": "/decks/019de070-d3cd-70da-8da9-11fac56c0e6a",
  "deckJsonHref": "/decks/019de070-d3cd-70da-8da9-11fac56c0e6a.json",
  "deckAnchorHref": "/decks/019de070-d3cd-70da-8da9-11fac56c0e6a#slide-21",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.4,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "list",
      "text": "Challenges: RNA Vaccine–Ultra Cold storage; Manufacturing: scale-up capacity; Most vaccines are 2 doses; Willingness of population to get vaccinated; Mutation of viral sequence may require new vaccines",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2a6998ca-baf8-400b-9006-1447998e1a87",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.4,
        "x": 0.53,
        "y": 0.25
      },
      "kind": "list",
      "text": "Unknowns: Long-term efficacy; Efficacy in diverse populations; Safety – Side effects; Vaccinated individuals still spread COVID; Efficacy on new mutations",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "88f7f480-2d25-4e5d-af9d-395ecf82386a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.5,
        "x": 0.05,
        "y": 0.03
      },
      "kind": "title",
      "text": "Vaccines are Just One Tool for COVID-19",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d4e2d90b-49b4-4d96-a567-6735b7e12511",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "0da7806a-f074-4d9d-8ed8-6f680c9e7a2a",
      "evidence": "list/bullet: Challenges: RNA Vaccine–Ultra Cold storage; Manufacturing: scale-up capacity; Most vaccines are 2 doses; Willingness of population to get vaccinated; Mutation of viral sequence may require new vaccines",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 21,
      "from": 20,
      "beatId": "f1ac50f0-1239-4611-9f0b-b49a7853e321",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Size",
      "beatSlug": "sequoia-pitch-market-size",
      "evidence": "Slides 20-21 discuss the potential markets for ANA001.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 22,
      "from": 21,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "172ba44a-d278-4002-99c0-0423cd9820d5",
      "evidence": "Slide 21 implies that the cost of inaction is high, and slide 22 shows recent deals for COVID antivirals.",
      "position": 0,
      "objective": "What is the cost of not having an effective COVID-19 treatment?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}